



**FOSUN 复星**  
共 创 幸 福  
SHARING HAPPINESS



Twitter



Facebook



LinkedIn



YouTube



Weibo



WeChat



Douyin (Tik Tok)



Fosun Alliance  
Wechat mini-program



Fosun Health  
Wechat mini-program

#### HONG KONG, CHINA

Address: Room 808, Icbc Tower, 3 Garden Road, Central  
Tel: + 852 2509 3228  
Fax: + 852 2509 9028

#### SHANGHAI, CHINA

Address: Building S1, Bund Finance Center, No. 600, Zhongshan East 2nd Road, Huangpu District  
Tel: + 86 21 2315 6666  
Fax: + 86 21 6130 3288  
Postcode: 200010

#### BEIJING, CHINA

Address: Beijing Fosun International Center, No. 237,  
Chaoyang North Road, Chaoyang District, Beijing  
Tel: + 86 10 59152299

#### NEW YORK, USA

Address: 28 Liberty Street, 44th Floor, New York, NY 10005, USA  
Tel: +1 646 553 5892

#### PARIS, FRANCE

Address: 15/17 Rue Scribe - 75009 Paris  
Tel: 00 33 (0) 1 46461199

#### LONDON, UK

Address: 2 Thomas More Square, Elwlyn, London  
Email: londonoffice@fosun.com

#### LISBON, PORTUGAL

Address: Largo Do Chiado 8, 1249-125 Lisbon, Portugal  
Tel: + 351 213 401 500



# FOSUN 复星

Rooted in China, Creating a Global Happiness Ecosystem  
Fulfilling the Needs of One Billion Families Worldwide in Health, Happiness and Wealth

# CONTENTS

02 | About  
Fosun

12 | Business  
Overview

24 | Fosun's  
Strategy

38 | Our  
Pursuit



# A GLOBAL INNOVATION-DRIVEN CONSUMER GROUP

Creating happier lives for families worldwide

## About Fosun

Fosun was founded in 1992. Our mission is to provide high-quality products and services for families around the world in Health, Happiness, Wealth, and Intelligent Manufacturing segments

Revenue 161.29 billion  
10-year Compound Growth 11%

Profit Attributable to Owners of the Parent 10.09 billion  
10-year Compound Growth 11%

Total Assets 806.37 billion

No. of Employees 96000

Forbes Global Ranking 2022 NO. 589

ESG Rating AA MSCI A HSI

Investment in Technology and Innovation 8.9 billion 1500+ Patents  
500+ New products in development

No. of C-end Customers 396 million Cumulative operable members<sup>1</sup>

\* Currency in RMB and data as of 31 December 2021 unless otherwise specified

<sup>1</sup> Operable members: Customers who have agreed to official member terms and conditions of the brand, have granted private personal information, including phone numbers, and are identifiable, reachable and traceable, are defined as registered members (i.e. operable members). From 2021 onwards, this statistic includes consumers in the Fosun Health ecosystem

ABOUT FOSUN



# OUR CLIENTS

One billion families worldwide





# MILESTONES

Fosun was founded in 1992 by graduates of Fudan University. Since its establishment, Fosun has implemented its twin-driver strategy of "Profound Industry Operations + Industrial Investment" to strengthen its foothold in various industries. Through continuous innovation, Fosun has achieved rapid development by capitalizing on the high-growth sectors that benefit from the momentum of China and the world's economic development

**1992**  
Founded with an initial investment of RMB38,000

**1994**  
Fosun Pharma Forte

**1998**  
Fosun Pharma listed on China's A-share market

**2002**  
Yuyuan Inc.

**2003**  
Nanjing Iron & Steel Sinopharm Group

**2007**  
Hainan Mining  
Fosun International (00656.HK) listed on HKEX

**2010**  
Club Med  
Henlius

**2011**  
BFC

**2012**  
Pramerica Fosun Life Insurance  
Peak Reinsurance  
Starcastle Senior Living

**2013**  
Atlantis Sanya  
Foshan Fosun  
Chancheng Hospital  
Sisram Med

**2014**  
Fidelidade  
Luz Saúde  
Roc Oil

**2015**  
Privatization of Club Med  
Thomas Cook  
Silver Cross

**2016**  
Gland Pharma  
H&A  
Wolverhampton Wanderers  
Babytree  
AHAVA

**2017**  
Fosun United Health Insurance  
Dongjia App

**2018**  
LANVIN  
Wolford  
Lovelink (formerly known as Baihe Jiayuan)  
Songhelou  
Fosun Tourism Group listed on HKEX

**2019**  
FFT  
Henlius listed on HKEX

**2020**  
DJULA  
WEI  
Jinhui Liquor  
Shede Spirits

**2021**  
Sergio Rossi  
Bankhaus Lampe  
Wansheng Co.

# LEADERSHIP



**Guo Guangchang**

Executive Director  
Chairman of the Company  
Founder of the Group

Aged 54, is an Executive Director and Chairman of the Company and the founder of the Group. As at the end of the Reporting Period, he has also been a director of both Fosun Holdings and Fosun International Holdings (the direct and indirect controlling shareholders of the Company, respectively), vice chairman of The General Association of Zhejiang Entrepreneurs, honorary chairman of The Zhejiang Chamber of Commerce, Shanghai, etc.. Mr. Guo was honored, among others, the “China Democratic League Anti-COVID-19 Outstanding Individual”, the “Anti-epidemic Action Award” at the “2020 Ram Charan Management Practice Awards” hosted by Harvard Business Review (Chinese version), the “Outstanding Businessman of Listed Company Award” at the “Top 100 Hong Kong Listed Company” Award, co-organized by Tencent News and Finet Group Limited, and “Lifetime Achievement Award” at the 16th CNBC Asia Business Leaders Award Ceremony etc.. Mr. Guo received a bachelor’s degree in philosophy in 1989 and a master’s degree in business administration in 1999, both from Fudan University. Mr. Guo is the controlling shareholder of the Company who is interested in and deemed interested in Shares and underlying shares of the Company, which represented approximately 72.73% of the total issued Shares as at the date of this annual report. Please refer to the section headed “INTERESTS AND SHORT POSITIONS OF DIRECTORS AND CHIEF EXECUTIVES IN SHARES, UNDERLYING SHARES AND DEBENTURES” in this annual report for details of his interest in the Shares and underlying shares of the Company.



**Wang Qunbin**

Executive Director  
Co-Chairman of the Company  
Founder of the Group

Aged 52, is an Executive Director and Co-Chairman of the Company, and the founder of the Group. Mr. Wang was a non-executive director of Fosun Pharma (listed on the Hong Kong Stock Exchange and the SSE) and Sinopharm (listed on the Hong Kong Stock Exchange). Mr. Wang was awarded “Asia Pacific Outstanding Entrepreneur Awards” by Enterprise Asia and “Best Asian Corporate Director” at the Asian Excellence Recognition Awards by Corporate Governance Asia, etc., and was named one of “China’s 50 Topperforming Corporate Leaders” by Harvard Business Review. Mr. Wang received a bachelor’s degree in genetic engineering from Fudan University in 1991.



**Chen Qiyu**

Executive Director  
Co-CEO of the Company

Aged 49, is an Executive Director and Co-CEO of the Company. Mr. Chen joined the Group in 1994 and as at the end of the Reporting Period, he has also been a non-independent director of Hainan Pharma (listed on the Hong Kong Stock Exchange and the SSE) and Shanghai Henlius (listed on the Hong Kong Stock Exchange), a non-executive director and vice chairman of Sinopharm (listed on the Hong Kong Stock Exchange), a co-chairman of New Frontier Health Corporation (delisted from the New York Stock Exchange in January 2022), a director of Gland Pharma (listed on the BSE Limited and National Stock Exchange of India Limited), Sanyuan Foods (listed on the SSE) and various companies within the Group. Mr. Chen was a director of Dian Diagnostics Group Co., Ltd. (listed on the Growth Enterprise Market Board of the Shenzhen Stock Exchange with stock code 300244) and a non-executive director of BabyTree (listed on the Hong Kong Stock Exchange). As at the end of the Reporting Period, Mr. Chen has been the chairman of China Medical Pharmaceutical Material Association, a vice chairman of China Pharmaceutical Innovation and Research Development Association, the honorary chairman and chief supervisor of Shanghai Biopharmaceutics Industry Association, and a member of the 13th Shanghai Standing Committee of the Chinese People’s Political Consultative Conference. Mr. Chen was awarded “Asia’s Best CEO” by Corporate Governance Asia, etc.. Mr. Chen received a bachelor’s degree in genetics from Fudan University in 1993 and an EMBA degree from China Europe International Business School in 2005.



**Xu Xiaoliang**

Executive Director  
Co-CEO of the Company

Aged 48, is an Executive Director and Co-CEO of the Company. Mr. Xu joined the Group in 1998, and as at the end of the Reporting Period, he has also been a non-independent director of Hainan Mining (listed on the SSE), a non-executive director of Fosun Pharma (listed on the Hong Kong Stock Exchange and the SSE) and Shanghai Foyo Culture & Entertainment Co., Ltd. (delisted from the NEEQ in April 2021) and various companies within the Group. Mr. Xu was a non-executive director and vice chairman of Zhaojin Mining Industry Co., Ltd. (listed on the Hong Kong Stock Exchange with stock code 01818, “Zhaojin Mining”), and a director of Shanghai Resource Property Consulting Co., Ltd. (delisted from the NEEQ in December 2020, “Resource Property”). As at the end of the Reporting Period, Mr. Xu has been a deputy to the 15th Shanghai Municipal People’s Congress, the co-chairman of Industry-City Integration Development Federation of The Zhejiang Chamber of Commerce, Shanghai and the chairman of Shanghai International Fashion Federation. Mr. Xu was awarded “Asia’s Best CEO” by Corporate Governance Asia, the “Shanghai 4 May Youth Medal” and “Shanghai Top Ten Youth Business People” etc.. Mr. Xu received a master’s degree in business administration from the East China Normal University in 2002 and received an EMBA degree from Fudan University in 2019.



**Qin Xuetao**

Executive Director  
Executive President  
of the Company

Aged 58, is an Executive Director and Executive President of the Company. Mr. Qin was appointed as the Executive President of the Company in August 2021. Since joining the Group in 1995, Mr. Qin has been in charge of the legal and internal control affairs of the Company, possessing in-depth knowledge in the area of mergers and acquisitions, as well as corporate governance of listed companies. In addition, Mr. Qin oversees all matters related to the Company’s audit, compliance, risk control and information disclosure. Mr. Qin received a bachelor’s degree in law in 1985 from the Southwest University of Political Science & Law and was admitted to practice law in the PRC in 1990. Prior to joining the Group, Mr. Qin worked in the Law School of Fudan University.



**Gong Ping**

Executive Director  
Executive President and  
CFO of the Company

Aged 46, is an Executive Director, Executive President and CFO of the Company. Mr. Gong was appointed as the Executive President of the Company in August 2021. Mr. Gong joined the Group in 2011 and as at the end of the Reporting Period, he has also been a director of Yuyuan (listed on the SSE) and various companies within the Group. He used to serve as a senior assistant to president of the Group, the general manager of Corporate Development Department and the CEO of Fosun Hive. He was the chairman of PAREF (listed on the Euronext Paris with stock code PAR), a non-executive director of Shanghai Zenda Property Limited (listed on the Hong Kong Stock Exchange with stock code 00755) and Fosun Pharma (listed on the Hong Kong Stock Exchange and the SSE), and a director of Shanghai Bailian Group Co., Ltd. (listed on the SSE with stock code 600827, “Shanghai Bailian”) and Resource Property (delisted from the NEEQ in December 2020). Prior to joining the Group, Mr. Gong worked at Pudong branch and the headquarters of Bank of Shanghai as well as the PRC headquarters of Standard Chartered Bank. Mr. Gong also served as a global strategist at the headquarters of Samsung Group in Korea, carrying out special assignments across various sectors including financial services, technology and real estate worldwide. As at the end of the Reporting Period, Mr. Gong has been a council member of Shanghai Association for Youth Entrepreneurship and Employment and vice chairman of Shanghai Youth Entrepreneurs’ Association. Mr. Gong graduated from Fudan University in 1998 with a bachelor’s degree in international finance, and then obtained his master’s degree in finance from Fudan University in 2005. Mr. Gong also received his master’s degree in business administration from International Institute for Management Development (IMD) in Lausanne, Switzerland in 2008.




**Huang Zhen**

Executive Director  
Executive President  
of the Company

Aged 50, is an Executive Director and Executive President of the Company. Mr. Huang was appointed as the Executive Director and the Executive President of the Company in March 2022. Mr. Huang joined the Group in 2017 and as at the end of the Reporting Period, he has also been the chairman of Yuyuan (listed on the SSE), the non-executive director of Zhaojin Mining (listed on the Hong Kong Stock Exchange) and the vice chairman of Baihe Jiayuan (delisted from NEEQ in December 2019), the director of Jinhui Liquor (listed on the SSE), Shede Spirits (listed on the SSE), Resource Property (delisted from NEEQ in December 2020), Shanghai Bailian (listed on the SSE) and various companies within the Group. Before joining the Group, Mr. Huang was the deputy general manager of Shanghai Jahwa United Co., Ltd., and the general manager of Shanghai Herborist Cosmetics Co., Ltd., etc. As at the end of the Reporting Period, Mr. Huang has been a member of the 3rd Shanghai Huangpu District Standing Committee of the Chinese People’s Political Consultative Conference, the chairman of Shanghai Huangpu District Federation of Industry and Commerce, the president of Shanghai Huangpu District Chamber of Commerce, the vice chairman of China Gold Association and Gems & Jewelry Trade Association of China, etc.. Mr. Huang was awarded “Top Ten Economic Figures in China’s Circulation Industry” and “National Outstanding Commercial Entrepreneur”, etc.. Mr. Huang received a bachelor’s degree in economics from Shanghai University of Finance and Economics in 1994 and an MBA degree from Webster University (USA) in 1998.



# GLOBAL BUSINESS FOOTPRINTS





# ONE FOSUN INDUSTRIAL ECOSYSTEM

As a global innovation-driven consumer group, Fosun is dedicated to developing a global FC2M ecosystem focusing on health, happiness and wealth. The “F” in FC2M stands for both “Family” and “Fosun”; C2M stands for Client to Maker

# BUSINESS OVERVIEW



# FOSUN FAMILY INDUSTRIAL ECOSYSTEM





# HEALTH BUSINESS

Transform the industry with technology to create healthier lives

Fosun adopts a global R&D + diversified innovation model (investment, incubation, BD, etc.) to create high-value innovative products in the fields of pharmaceutical, devices, and diagnosis

## PHARMACEUTICALS

Fosun Pharma continues to increase investment in innovation and R&D to promote innovation and transformation

**FOSUN PHARMA**  
复星医药

**FOSUNKite**  
复星凯特生物

**GLAND**

**Henlius**

**FOSUN ADGENVAX**  
复星安特金

## MEDICAL DEVICES & DIAGNOSTICS

The medical devices & diagnostics segment has initially formed three business branches centered on medical beauty, respiratory health, and professional medical care

**FOSUN MEDTECH**  
复星医疗器械

**Sisram**  
medical

**BREAS**  
博毅雅

**INTUITIVE FOSUN**  
直观复星

**CHINDEX**

Medical Diagnostics: Integrate innovative diagnostic technologies to protect health for all



In April 2022, Fosun Diagnostics' self-developed COVID-19 Antigen CARD Kit received China National Medical Products Administration's (NMPA) approval for commercialization



In March 2020, Fosun Diagnostics' self-developed COVID-19 RT-PCR detection kit received NMPA's approval for emergency use and obtained the Registration Certificate for Medical Device (in vitro diagnostic reagents)

**FOSUN DIAGNOSTICS**  
复星诊断

## HEALTHCARE SERVICES AND PRODUCTS

Build a one-stop health management platform covering the full life-cycle;  
Develop maternal and child consumer goods, health platform, healthy food, creating product + consumer traffic portal

**FOSUN HEALTH**  
复星健康

**FHC**  
复星医疗  
FOSUN HEALTHCARE

**复星星堡**  
FOSUN STARCASTLE

**复星杏脉**  
FOSUN AITROX

**国药集团**  
SINOPHARM GROUP

**FOSUN HEALTH**  
复星联合健康保险

**LUZ SAÚDE**

**三元食品**  
SANYUAN

**JOYFUL WAY**  
卓尔荟

**babytree**  
宝宝树

**佛山复星禅诚医院**  
Foshan Fosun Chancheng Hospital

Over 25%

Revenue contribution of new and sub-new products

RMB 4.98 billion

Fosun Pharma's R&D investment in 2021

China's first approved CAR-T cell therapy

奕凯达® (Yi Kai Da, Aquilence Injection) has been included in the 2022 edition of "Huhuibao" (a supplementary medical insurance in Shanghai). As of the end of May 2022, it has been included in "Huimin Insurance" (civil affordable insurance scheme) and more than 50 commercial insurances in 32 provinces and cities, the number of treatment centers on file has reached 81, and benefited more than 200 patients in China

China's first biosimilar

汉利康® (Han Li Kang, Rituximab Injection) generated a revenue of RMB1.69 billion in 2021, representing a yoy increase of 125.3%

42.3%

Sisram Medical's yoy R&D investment increase in 2021

Over 270

da Vinci Surgical Systems installed in Chinese Mainland, Hong Kong SAR and Macau SAR as of the end of 2021

Over 5000

Beds in member hospitals

39%

Fosun United Health's yoy premium growth

Over 240

Pipeline projects including new drugs in development, generic drugs, biosimilars and quality consistency evaluation of generic drugs

Over 24 million doses of Comirnaty®  
(mRNA COVID-19 vaccine)

Administered in Hong Kong SAR, Macau SAR and Taiwan region, as of March 2022

China's first independently developed monoclonal antibody approved in both China and Europe

汉曲优® (Zercepac®, Trastuzumab injection) achieved a revenue of RMB930 million in 2021

Gland Pharma

Revenue increased by 29.48%\* yoy in 2021

\* According to the financial statements of Gland Pharma

81.6%

Sisram Medical's yoy revenue growth in 2021

Over 10 million

Surgeries operated by da Vinci Surgical System

Ranked first among China's Non-Public Hospitals (in terms of competitiveness)

Fosun Foshan Chancheng Hospital

2500+ Employed Doctors, 200K+ Partner Doctors

Fosun Health integrates resources in the health ecosystem



# HAPPINESS BUSINESS

Develop contents, models and products for families  
to link online platforms and offline scenarios

## YUYUAN INC.

As one of the flagship platforms of Fosun Happiness segment, Yuyuan Inc. takes "Oriental Aesthetics" as its core and promotes Chinese culture to the world  
Jewelry and Fashion



Food and Beverage



Liquor



Chinese Watches



Beauty & Health



## FOSUN TOURISM GROUP

As another flagship platform of the Happiness segment, Fosun Tourism is the world's largest leisure resort group, and is striving to build the new lifestyle of "Everyday is Holiday", infusing evolving concepts of tourism and leisure into everyday living



## LANVIN GROUP

A grand transformation. Fosun Fashion Group rebranded to LANVIN GROUP, entering a new chapter



## MORE HAPPINESS

Centered around sports, e-sports, film and television, and games to create a diversified entertainment experience of Fosun



3981

Points of Sale

### Enter the Liquor Industry

Investment + Operations as twin-driver

Time-honored brands with more than 200 years of history pass on the heritage;

Reshape the future with globalization

### Sanya's Tourism 3.0 Benchmark

4.7 million visits in 2021

Covering 80 +

Countries and regions

300+

Self-operated retail stores

10000+

Dongjia's craftsmen

80 +

The chain development of Songhelou noodle restaurant was further implemented

### Two Chinese watchmakers

One Chinese chip

Spanning across five continents with nearly 70 resorts

Club Med 17 new resorts to be opened from 2022 to 2024

The world's oldest travel agency with 180 years of history

Thomas Cook App has been downloaded 2.6 million times

Approx. 1200

Points of sale

25 %

Lovelink's revenue growth in 2021

Wolverhampton Wanderers Football Club (Premier League)

Wolves Esports



# WEALTH BUSINESS

Fosun actively expands into personal finance, corporate finance and investment businesses globally and accelerates the development of innovative finance driven by technology. Fosun continuously strengthens the seamless docking capability of "Industry + Finance", capturing opportunities of global industrial integration

## INSURANCE

Establish a global landscape and adhere to innovative development and insurance ecosystem development



## INVESTMENT MANAGEMENT

Industrial investment + financial investment as twin-driver to empower Health, Happiness, Wealth, and Intelligent Manufacturing in every aspect of life



RMB 62.6 billion

Premium

29.1%

Fosun Insurance Portugal's market share in Portugal in 2021

EUR 230 billion

Assets under HAL's service ad management

EUR 1.29 billion

BCP's consolidated core net income

China's Top Private Equity Investment Institution in 2021

Fosun Capital

40+

Global Fosun Hive Cities

RMB 174.2 billion

Investable assets

USD 2.1 billion

Peak Reinsurance's gross written premium in 2021

+37%

Growth in assets under HAL's service and management

+10.9%


BCP's yoy consolidated core net income growth

Top 100 Chinese Venture Capital Institutions in 2021

Fosun RZ Capital

130+

Global Fosun Hive Projects





# INTELLIGENT MANUFACTURING BUSINESS

Develop digital intelligence globally to empower industrial manufacturing

Fully implement the C2M model and leverage big data, artificial intelligence, IoT, and other emerging technologies to promote intelligent manufacturing

## INTELLIGENT MANUFACTURING INDUSTRY



## GREEN RESOURCE INDUSTRY



RMB 75.67 billion

Nanjing Iron & Steel's revenue in 2021

+513.55%

Hainan Mining's net profit attributable of owners of the parent yoy growth

RMB 4.09 billion

Nanjing Iron & Steel's net profit attributable to owners of the parent in 2021

20,000 tons

Output of the battery-grade lithium hydroxide project that Hainan Mining planned to invest



## FOSUN'S STRATEGY

---

A nighttime photograph of a city skyline, likely Shanghai. In the foreground, there are traditional Chinese buildings with ornate, illuminated roofs. Behind them, a dense cluster of modern skyscrapers is visible, many of which are brightly lit. The sky is dark, and the overall scene is a mix of old and new architecture.

# FOSUN'S STRATEGY



# SUSTAIN RESILIENCE AND ACCUMULATE CAPABILITIES TO EMPOWER THE FUTURE: FOUR CORE COMPETENCIES

## Globalization

"Global organization + local operations" to promote Fosun's global industrial ecosystem with cross-regional, cross-cultural and cross-organizational operational capabilities, providing new impetus for the improvement and expansion of Fosun's industry operations

## FC2M Ecosystem


Form multiple vertical C2M ecosystems with C2M closed loop of various industries; connect the vertical C2M ecosystems horizontally and realize multiplier effect to form a "FC2M ecosystem"  
Enhance industrial capabilities through comprehensive digital intelligence to connect all ecosystems

## Innovation-driven

Driven by product innovation  
Driven by digital intelligence innovation  
Driven by management innovation

## FES

Fosun Entrepreneurship / Ecosystem System provides systematic methodology, tools and processes to realize Fosun's globalization, innovation and ecosystem operation





# GLOBAL + LOCAL TWIN-DRIVER



**GLOBAL FOOTPRINTS**

Profound industry operations in nearly 30 countries and regions across five continents in the world



**GLOBAL BUSINESSES**

Over 40% of the revenue in 2021 generated from overseas countries or regions



**GLOBAL INNOVATION**

Focus on America, Africa, India, and Europe, build up diversified regional and global capabilities



**GLOBAL TALENTS**


More than 20 overseas partners among over 140 global partners



<sup>1</sup> Mutual empowerment revenue includes: revenue generated from the introduction of overseas technologies, products and services into the Chinese market, and revenue from the export of outstanding Chinese technologies and products to overseas markets




# FC2M ECOSYSTEM ENHANCES QUALITY AND EFFICIENCY OF INDUSTRY OPERATIONS



<sup>1</sup> Operable members: Customers who have agreed to official member terms and conditions of the brand, have granted private personal information, including phone numbers, and are identifiable, reachable and traceable, are defined as registered members (i.e. operable members). From 2021 onwards, this statistic includes consumers in the Fosun Health ecosystem

Overview of Fosun's ecosystem: intelligent connection, open coopetition, global empowerment, multiplier development  
Strategy of Fosun's ecosystem: make a concerted effort to strive for a common goal and share rewards to realize multiplier effect within the ecosystem



Notes:  
1. The companies are listed according to the consolidated financial statement of Fosun International  
2. The companies are some of the strategic suppliers of Fosun  
3. The companies are some of the strategic partners of Fosun



# INNOVATION-DRIVEN

Fosun has always considered "innovation-driven" as one of its core competencies, and has long adhered to an innovation-driven strategy, creating products and solutions with technologies to address unmet needs

Fosun has built a multi-dimensional innovation system with independent research and development, investment incubation, patent licensing, and the introduction of innovative products through cooperation

Innovation-driven development is Fosun's key strategy. In 2021, Fosun invested RMB8.9 billion in technology and innovation. It has obtained more than 1,500 patents and has more than 500 new products in development to build core competitiveness

- In June 2021, China's first CAR-T cell therapy, 奕凯达® Yi Kai Da (Aquilece Injection) was approved for launch, opening a new era of CAR-T cell therapy in China

- As of the end of May 2022, it has been included in "Huimin Insurance" (civil affordable insurance scheme) and more than 50 commercial insurances in 32 provinces and cities, the number of treatment centers on file has reached 81, and benefited more than 200 patients in China

- The National Sliding Centre, "Snow Dragon" (雪游龙), is the venue for bobsled, luge, and skeleton events at the Beijing Winter Olympics 2022, and the first sliding track in China. It has a total length of 1975 meters, a vertical drop of 121 meters and 16 curves. Since the track is exposed to open air while ice has to be generated repeatedly on the surface, it also has to withstand a temperature of minus 40 degrees Celsius, the steel plate must possess strong atmospheric corrosion resistance and maintain its structure at ultra low temperatures

- Nanjing Iron & Steel took up the important task and the team debugged the special process by incorporating phosphorus and other trace elements to the steel to create a "protective film", which ultimately created a resilient weathering steel to build "Snow Dragon" to make sure the games can run smoothly



Two engineers of Fosun Kite Tianci production team are discussing technical details



Nanjing Iron & Steel customized weathering steel for "Snow Dragon" (雪游龙) in the Beijing Winter Olympics



# TECHNOLOGY AND INNOVATION CAPABILITIES AS INDUSTRY ADVANTAGE

Investment in 2021

RMB **8.9** billion<sup>1</sup>

Strengthening technology and innovation capabilities

**500+**

New products in development

**1500+**

Patents

## LEADING

### CORE TECHNOLOGIES IN VARIOUS FIELDS



The world's leading integrated solutions provider for the automation and digital industries



Technological innovation enterprise engaged in medical imaging and pathology AI software and digital solutions



Focus on tumor cell therapies; China's first approved cell therapy

## INNOVATIVE

### R&D CENTERS IN VARIOUS FIELDS

- Fosun Pharma Global R&D Center (national level)
- JEVE Technology Center (national level)
- Wanbang Biopharma Quality Department QC Lab<sup>2</sup> (CNAS certified)
- Fosun Cosmetics Innovation Center<sup>2</sup>
- Fosun Pharma North America R&D Headquarters
- Shanghai Key Laboratory of Stem Cell Therapy
- Sichuan Engineering Technology Center for Intelligent Brewing of White Liquor
- Lanvin Design Center (Milan and the U.K.)
- Yuyuan Jewelry Creative House
- NISCO U.K. Research Centre
- National Material Environmental Corrosion Platform
- Nanjing Atmospheric Station
- Academician Enterprise Research Institute
- ...

汉利康® Han Li Kang

China's first biosimilar

汉曲优® Zercepac®

China's first independently developed monoclonal antibody approved in both China and Europe



奕凯达® Yi Kai Da

China's first approved CAR-T cell therapy



More than 140

Featured insurance products and health management services



Special steel with weather resistant 8 times that of ordinary steel

Was used to build the "Snow Dragon" in the Beijing Winter Olympic Games

Certified by ship classification societies of 7 countries

Developed 100mm thick crack arrest steel, breaking foreign technical barriers to build massive 24000TEU container ships



<sup>1</sup>Including R&D investment (expensed and capitalized R&D investment) and excluding investment in digitalization

<sup>2</sup> Application of CNAS (China National Accreditation Service for Conformity Assessment) certified laboratory is in progress



# TECHNOLOGY AND INNOVATION CAPABILITIES AS INDUSTRY ADVANTAGE


FES

(Fosun Entrepreneurship / Ecosystem System)

The FES system is a continuously evolving management system that helps Fosun build core competitiveness of a longstanding enterprise and nurture talents with Fosun's entrepreneurship


The system provides Fosun with systematic methodology, tools, and processes to realize globalization, technology innovation and smooth operation of Fosun's ecosystem

With the joint effort of all employees, a corporate culture of continuous improvement and continuous growth will be established, promoting the contribution of the "Power of Fosun" to the development of the whole society



Profound Industry Operations + Industrial Investment

Accumulation  
Practice



100+  
Professional tools

50+  
Core Enterprises  
FES Talent Program

400+  
Improvement  
activities annually

700+  
Expert  
certification annually



# FOCUS ON KEY TALENTS TO BUILD A TEAM WITH ENTREPRENEURIAL SPIRITS

TALENTS, THE MOST VALUABLE ASSET OF FOSUN  
A ROBUST TEAM OF TALENTS DETERMINES THE SCALABILITY OF THE COMPANY’S FUTURE DEVELOPMENT



## Our elite management team

140+ global partners, 240+ industry partners,  
350+ functional line partners, 60+ innovation partners  
with regular rotation to deeply involve in each project, sector, and region

## GLOCAL

20+ overseas global partners coming from countries including Portugal,  
France, Germany, the U.K., Japan, India, and the U.S

## Fosun’s talent development strategy

Attract talents with development, appraise talents based on performance,  
train talents through works, and unite talents with career opportunities

Build a multi-level and multi-dimensional partner system, incentivize partners, and adhere to a market-based, benefit-sharing entrepreneurial mechanism



### FOSUN GLOBAL PARTNERS

300 +

Future Fosun global partners



### ELITE ENTREPRENEURS

3000 +

Future entrepreneur backups



### YOUNG ENTREPRENEURS

30%

Young talents



### TECHNOLOGY AND INNOVATION TALENTS

140 +

Top scientists of Fosun ecosystem

## Future Fosun Global Partners Backups

Create a “pyramid” partner backup array,  
forming a competitive dynamic partnership management mechanism that allows talent appraisals  
at different levels according to their performance



SHARING HAPPINESS



OUR

PURSUIT



# REMARKABLE ESG ACHIEVEMENTS FOR A BRIGHTER LIFE

MSCI

ESG RATINGS

CCC B BB BBB A AA AAA

LAST UPDATE: December 27, 2021

恒生可持續發展  
企業指數系列

Jumped from A to AA

The only conglomerate in Greater China with a MSCI ESG rating of AA


A

Selected as a constituent of the Hang Seng ESG 50 Index and the Hang Seng Corporate Sustainability Benchmark Index (top 20%)

ESG RATINGS CONTINUED TO IMPROVE IN 2021

ESG Governance

Optimize ESG governance structure and link the Group's ESG performance with the performance appraisal of the Board of Directors



## CARBON NEUTRALITY STRATEGY

Nanjing Iron & Steel low carbon products, photovoltaic power generation , intelligent equipment

Fosun Tourism Group received a MSCI ESG rating of AA

Safety & Environmental Protection Policy

## BUSINESS FOR GOOD

- Anti-epidemic efforts
- Rural Doctors Program
- Global health promotion

## CORPORATE GOVERNANCE

- Continues to optimize the governance structure
- Enhance the diversity of the governing body
- Conducts transparent tax strategy and issued the Fosun Group Tax Guiding Principles

# FOSUN FOR GOOD



The Fosun Foundation was established in November 2012 as the main humanitarian arm of the Fosun Group and is a “5A Social Organization” . Adhering to Fosun's philosophy of “Self-improvement, Teamwork, Performance and Contribution to Society” , Fosun Foundation insists on serving the society, the people and the nation. The coverage of the foundation includes disaster relief, healthcare, poverty alleviation, rural revitalization, education, community building, youth entrepreneurship and culture, art, etc., serving many countries and regions around the world

## FOSUN FOUNDATION (SHANGHAI)

Fosun Foundation (Shanghai) is a non-profit organization launched and supported by the Fosun Group and Fosun Foundation. Its programs are characterized by contemporary, international, and highly interactive artworks. It has held a total of 22 art exhibitions and has attracted more than 1.3 million visits since 2016

## PROTECTING

### GLOBAL YOUTH START-UP ACCELERATION PROGRAM

Received 896 applications from 40+ countries and regions since 2016  
Won 3 international awards in recognition of its corporate social responsibility  
33 closely cooperated start-up projects  
5 companies signed commercial contracts

## ASSIST AFRICA IN FIGHTING AGAINST MALARIA

Fosun Pharma supplied over 200 million artesunate injections to the international market, benefited over 40 million patients with severe malaria, most of whom were under five years old

## RURAL DOCTORS POVERTY ALLEVIATION PROGRAM

Up to now, the program has covered 73 counties in 16 provinces, municipalities, and autonomous regions  
Sent a total of 226 staff to assist the counties  
Served approx. 24,000 rural doctors  
Benefited 3 million grassroots families

## TAI CHI ANTI-PARKINSON'S DISEASE, TAI CHI FOR DELAYING ALZHEIMER'S DISEASE

The scientific research findings of Tai Chi as an adjuvant therapy for chronic diseases were published in international authoritative journals  
Organized 3039 hours of Tai Chi charitable courses for 443 patients with Parkinson's disease since 2015  
Organized 541 hours of online Tai Chi charitable courses, benefited 19042 people since 2020



# FOSUN FOUNDATION (SHANGHAI)

Fosun Foundation (Shanghai) aims to promote contemporary art and is committed to binding Chinese and international art and culture, and promote public awareness, understanding and engagement in global contemporary art. Fosun Foundation (Shanghai) continues to support local Chinese artists, providing a broad display platform for outstanding Chinese contemporary art works. Fosun Foundation (Shanghai) is located in the Bund Finance Center. Fosun Foundation (Chengdu) will open in June 2022. Fosun Foundation (Shanghai) participates in, witnesses and leads the development of contemporary art and culture. As an art consultant, Fosun Foundation (Shanghai) has long showcased its collection of Chinese art works in global landmark buildings such as Liberty 28 in New York to promote global cultural and artistic exchanges

## 22 art exhibitions

1.30 million + visits

Committed to presenting international and Chinese contemporary art exhibitions and special exhibitions with rich content, including “Tadao Ando: Endeavors”, “Yayoi Kusama: All About Love Speaks Forever”, etc.


## 410+ public education campaigns

32800+ people participated in public education campaigns

Insist on organizing high-quality public education campaigns to help the public understand art and promote active participation in art-related events

## 290+ Fosun Foundation (Shanghai) Night and Aesthetic Journey

Organize diversified and comprehensive cross-brand activities to promote public awareness and public engagement in the latest contemporary art trends





# FIGHT AGAINST COVID-19: STAY TRUE TO ITS ORIGINAL ASPIRATION AND CONTRIBUTE TO SOCIETY

**SPRING ANTI-EPIDEMIC ACTION** (From 11 March 2022 – 18 June 2022)

## 6.245 million pieces

Anti-epidemic materials donated by Fosun Foundation and its partners as of 9 June 2022 to support the three projects, “Community Support”, “Care for Elderly” and “Care for Children” in Shanghai’s battle against COVID-19

## 1.204 million pieces

Materials donated to government departments and public institutions

## 1.203 million pieces

Materials donated to education system

## 1.366 million pieces

Materials donated to hospitals, mobile cabin hospitals, and other health facilities

## 953

Community needs addressed

## 2.093 million pieces

Anti-epidemic and daily necessities donated



## SUPPORT CHINA’S FIGHT AGAINST COVID-19 (From 24 January 2020 – present)

### Deployed nearly 3 million pieces of materials globally

These strategic materials provide strong support for China's fight against COVID-19

When the COVID-19 epidemic broke out in early 2020 and China was in the most difficult time, Fosun leveraged its strong global resources deployment capability to source medical supplies from 23 countries. On 28 January 2020, the first batch of materials deployed by Fosun, 50,000 pieces of protective suits deployed from Germany, was delivered from Frankfurt to front-line medical staff in Wuhan and other front-line medical staff in just 5 days

## More than 400

Negative pressure ambulances put into use

## Fosun continues to assist Hong Kong SAR, Shenzhen, Jilin, Shanghai, etc.

The Omicron variant fueled outbreaks in many areas in 2022

## GLOBAL RESPONSIBILITY (From 1 March 2020 – present)

## 147 million pieces

Anti-materials donated, such as COVID-19 nucleic acid testing kits, ventilators, face masks, protective suits, and gloves, for humanitarian relief support against COVID-19

## More than 18000

Ventilators put into use in the global fight against COVID-19

## Assisted 30+ countries

Fosun's self-developed COVID-19 nucleic acid detection kit has been certified by the China NMPA and the U.S. Food and Drug Administration (FDA), and obtained the European Union CE marking

## Rolled out in Hong Kong SAR, Macau SAR and Taiwan region

mRNA-based COVID-19 vaccine developed in collaboration with BioNTech

## Obtained rights to produce generic versions of the Pfizer and Merck's oral COVID-19 treatment

Through the Medicines Patent Pool (MPP)

## More than 20000

Oxygen concentrators provided to support India's fight against COVID-19

## 100000

Pieces of KN95 face masks

# RURAL DOCTORS PROGRAM

## Delivering hope to impoverished people in rural areas

The Rural Doctors Program is one of the key initiatives to realize the goal of common prosperity. In late 2017, under the guidance of the National Health Commission Poverty Relief Office, Fosun Foundation, together with China Population Welfare Foundation, etc., initiated the Rural Doctors Poverty Alleviation Program ( “Rural Doctors Program” ) to empower millions of rural doctors who are working in the frontlines, thereby accelerating the realization of Healthy China

## 4 years, 226

On-site workers

## 16

Provinces, cities, autonomous regions covered across the country

## 73

Key national poverty-stricken counties

(including 13 counties in Three Regions and Three Prefectures in extreme poverty, which have all lifted out of poverty)

## 12545

Administrative village clinics assisted

## 23956

Rural doctors served

## 3 million

Grass-root families benefited



In September 2021, the Rural Doctors Program was awarded the "China Charity Award" for its remarkable contributions



# FIGHT AGAINST MALARIA IN AFRICA

## Assist in building a “malaria-free world”

## 2.4 billion +

The number of vials of artesunate for injection (60mg) that Fosun Pharma supplied to the global market since 2005, according to incomplete statistics

## 48 million +

The number of patients with severe malaria that Artesun® (artesunate for injection) has saved, most of which are African children under five years old



## 175 million

The number of children in high malaria transmission African countries benefited from SPAQ-CO®Disp, a malaria prevention drug for children which was pre-qualified by the World Health Organization

“We will join forces and work with anti-malaria experts as well as other parties to continue to carry out malaria education projects for the public and raise the public awareness of malaria prevention. We will also actively participate in public health improvement and make steady efforts to build a malaria-free world.”

— Guo Guangchang





# TAI CHI ANTI-PARKINSON'S DISEASE, TAI CHI FOR DELAYING ALZHEIMER'S DISEASE

## Slow therapy for chronic disease to hold on to the good memories

Fosun Foundation cooperated with the Neurology Department of Ruijin Hospital to jointly launch "Tai Chi Anti-Parkinson's Disease" and "Tai Chi for Delaying Alzheimer's Disease"

### TAI CHI ANTI-PARKINSON'S DISEASE

443

Patients with Parkinson's disease served since 2015

3039 hours

Charitable course organized

541 hours

Online Tai Chi course organized since 2020

19042

People benefited

### TAI CHI FOR DELAYING ALZHEIMER'S DISEASE

26

Patients with Alzheimer's disease served

160 hours

Tai Chi charitable course organized



Research Results of the Two Programs

### COMMUNITY TAI CHI VOLUNTEER INSTRUCTOR TRAINING

4

Community served

126

Elders served

33

Tai Chi volunteers trained



# BETTER PROTECTION FOR FAMILIES

Comirnaty® (mRNA COVID-19 vaccine, BNT162b2)

## JOINT DEVELOPMENT EFFORTS OF CHINA AND GERMANY

Continuously ensures the supply of vaccines for the Greater China region in the hope of building an immunity barrier

2020

In March 2020, Fosun Pharma obtained the license from BioNTech to exclusively develop and commercialize BioNTech's COVID-19 vaccine based on its proprietary mRNA technology platform in the Chinese Mainland, Hong Kong SAR, Macau SAR, and Taiwan region

2021

Comirnaty® was included in the government vaccination programs in Hong Kong SAR and Macau SAR in March 2021, and administered in Taiwan region since September 2021

2022

As of the end of March 2022, more than 24 million doses of Comirnaty® (mRNA COVID-19 vaccine) have been administered in Hong Kong SAR, Macau SAR and Taiwan region, assisting the regions to build a COVID-19 immunity barrier

- In May 2022, the preprint platform, The Lancet, published the Phase II clinical study of Fosun Pharma's mRNA COVID-19 vaccine, Comirnaty® (BNT162b2)". Research findings show that two doses of Comirnaty® administered 21 days apart in healthy Chinese individuals and Chinese individuals with stable underlying disease would induce a strong immune response with a favorable safety profile
- On 27 February 2021, the first batch of Comirnaty® (mRNA COVID-19 vaccine) arrived in Hong Kong SAR from Germany

